On 12/9/24, Revance Therapeutics Inc (NASDAQ: RVNC) stock suffered a major decline of -20.7%, closing at $3.03. Moreover, this decline was accompanied by exceptionally high trading volume at 932% of normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -16.1% during the last week.
Current PriceTarget Research Rating
Revance Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment